Lundbeck launches Circadin in central Europe
This article was originally published in Scrip
Lundbeckhas launched Circadin (sustained-release melatonin), its short-term treatment of primary insomnia in patients aged 55 or more, in Poland, Hungary and the Czech Republic. The condition affects up to 10% of the total population and up to 25% of older people. The product, which mimics the release of melatonin governed by the patient's circadian rhythm, is the first of this type of insomnia therapy approved by the European Medicines Agency. Its clinical trials showed a significant improvement in the quality of sleep in almost half of patients taking Circadin and improved morning alertness in nearly 40%. The company said Circadin does not cause dependency.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.